Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Interferon Alfa-2b in Stage II or III Melanoma
NCT00003641Phase 3Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Mar 1999
- Primary completion
- Jan 2015
- Modality
- Cytokines & Interferons
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Observation with Interferon Alfa-2b (2 arms). Primary endpoint: Relapse-Free Survival Rate at 5 years. Started Mar 1999; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003641.